197 related articles for article (PubMed ID: 9920790)
1. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
[TBL] [Abstract][Full Text] [Related]
2. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green.
Hiratsuka M; Agatsuma Y; Mizugaki M
Mol Genet Metab; 1999 Nov; 68(3):357-62. PubMed ID: 10562462
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
Yilmaz N; Erbağci AB; Aynacioğlu AS
Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
6. [Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Ned Tijdschr Geneeskd; 2001 Feb; 145(7):312-5. PubMed ID: 11234294
[TBL] [Abstract][Full Text] [Related]
7. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
[TBL] [Abstract][Full Text] [Related]
9. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
10. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
[TBL] [Abstract][Full Text] [Related]
11. [Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced influenza-virus-associated encephalopathy].
Funato T; Kozawa K; Kaku M
Rinsho Byori; 2002 Feb; 50(2):140-5. PubMed ID: 11925850
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
13. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
14. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
15. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies.
Sipeky C; Lakner L; Szabo M; Takacs I; Tamasi V; Polgar N; Falus A; Melegh B
Blood Cells Mol Dis; 2009; 43(3):239-42. PubMed ID: 19541511
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.
Aquilante CL; Lobmeyer MT; Langaee TY; Johnson JA
Pharmacotherapy; 2004 Jun; 24(6):720-6. PubMed ID: 15222661
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Bigler J; Whitton J; Lampe JW; Fosdick L; Bostick RM; Potter JD
Cancer Res; 2001 May; 61(9):3566-9. PubMed ID: 11325819
[TBL] [Abstract][Full Text] [Related]
19. Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations.
Nakai K; Habano W; Nakai K; Fukushima N; Suwabe A; Moriya S; Osano K; Gurwitz D
Life Sci; 2005 Nov; 78(1):107-11. PubMed ID: 16111713
[TBL] [Abstract][Full Text] [Related]
20. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
